INDs in immuno-oncology : accommodating changes in CAR constructs or manufacturing process | Neil Sheppard | Stem Cell Jungle

Is the FDA adapting to cell therapies ? How ?...

21 September, 2022

Off-the-shelf T and NK cells : benefits of allogeneic strategies in immuno-oncology | Neil Sheppard | Stem Cell Jungle

What's the medical need for allogeneic anti-tumor therapies ? What...

21 September, 2022

The challenge of targeting solid tumors with T cells, TIL therapies, TCR Ts | Neil Sheppard | Stem Cell Jungle

While solid tumors represent the vast majority of cancers, most...

21 September, 2022

Filling gaps of autologous CAR-T : opportunities and challenges of allogeneic cell therapies | Neil Sheppard | Stem Cell Jungle

In which cases could allogeneic strategies be used instead of...

21 September, 2022

The promise of NK cells in immuno-oncology, Mode of Action, Comparison with Ts, Safety profile | Neil Sheppard | Stem Cell Jungle

Neil Sheppard, D.Phil, Adjunct Associate Professor in the Department...

21 September, 2022

iPSC-derived NK cells versus T cells : differentiation, amplification, in vivo function | Neil Sheppard | Stem Cell Jungle

Neil Sheppard, D.Phil, Adjunct Associate Professor in the Department of...

21 September, 2022